HRP20100677T1 - IMIDAZO[1,2-a]PIRIDINSKI SPOJEVI KAO INHIBITORI VEGF-R2 - Google Patents
IMIDAZO[1,2-a]PIRIDINSKI SPOJEVI KAO INHIBITORI VEGF-R2 Download PDFInfo
- Publication number
- HRP20100677T1 HRP20100677T1 HR20100677T HRP20100677T HRP20100677T1 HR P20100677 T1 HRP20100677 T1 HR P20100677T1 HR 20100677 T HR20100677 T HR 20100677T HR P20100677 T HRP20100677 T HR P20100677T HR P20100677 T1 HRP20100677 T1 HR P20100677T1
- Authority
- HR
- Croatia
- Prior art keywords
- optionally substituted
- alkyl
- 4nr2r3
- phenyl
- nhr
- Prior art date
Links
- 150000005234 imidazo[1,2-a]pyridines Chemical class 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- -1 amino, methyl Chemical group 0.000 claims abstract 21
- 101100516563 Caenorhabditis elegans nhr-6 gene Proteins 0.000 claims abstract 17
- 150000001875 compounds Chemical class 0.000 claims abstract 15
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims abstract 9
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims abstract 7
- 125000001424 substituent group Chemical group 0.000 claims abstract 7
- 125000002757 morpholinyl group Chemical group 0.000 claims abstract 6
- 229910052736 halogen Inorganic materials 0.000 claims abstract 5
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims abstract 5
- 125000004076 pyridyl group Chemical group 0.000 claims abstract 5
- 125000000335 thiazolyl group Chemical group 0.000 claims abstract 5
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims abstract 5
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims abstract 4
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract 4
- 239000001257 hydrogen Substances 0.000 claims abstract 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims abstract 4
- 125000003226 pyrazolyl group Chemical group 0.000 claims abstract 4
- 125000000714 pyrimidinyl group Chemical group 0.000 claims abstract 4
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 claims abstract 3
- 125000005843 halogen group Chemical group 0.000 claims abstract 3
- 150000002367 halogens Chemical group 0.000 claims abstract 3
- 125000003386 piperidinyl group Chemical group 0.000 claims abstract 3
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims abstract 3
- 150000003839 salts Chemical class 0.000 claims abstract 3
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims abstract 3
- 125000001544 thienyl group Chemical group 0.000 claims abstract 3
- 125000004448 alkyl carbonyl group Chemical group 0.000 claims abstract 2
- 125000002883 imidazolyl group Chemical group 0.000 claims abstract 2
- 125000001786 isothiazolyl group Chemical group 0.000 claims abstract 2
- 125000000842 isoxazolyl group Chemical group 0.000 claims abstract 2
- 229910052757 nitrogen Inorganic materials 0.000 claims abstract 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims abstract 2
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims abstract 2
- 125000002971 oxazolyl group Chemical group 0.000 claims abstract 2
- 125000004193 piperazinyl group Chemical group 0.000 claims abstract 2
- 125000001412 tetrahydropyranyl group Chemical group 0.000 claims abstract 2
- 125000001113 thiadiazolyl group Chemical group 0.000 claims abstract 2
- 125000001425 triazolyl group Chemical group 0.000 claims abstract 2
- 239000003814 drug Substances 0.000 claims 3
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 230000033115 angiogenesis Effects 0.000 claims 2
- 230000000903 blocking effect Effects 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 239000012453 solvate Substances 0.000 claims 2
- HTQYWLPDWPCWTF-UHFFFAOYSA-N 2-[2-fluoro-4-[7-(2-methylpyridin-4-yl)imidazo[1,2-a]pyridin-3-yl]phenyl]-n-[3-(trifluoromethyl)phenyl]acetamide Chemical compound C1=NC(C)=CC(C2=CC3=NC=C(N3C=C2)C=2C=C(F)C(CC(=O)NC=3C=C(C=CC=3)C(F)(F)F)=CC=2)=C1 HTQYWLPDWPCWTF-UHFFFAOYSA-N 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- XEKBGOVZNHDHET-UHFFFAOYSA-N n-(5-tert-butyl-1,2-oxazol-3-yl)-2-[2-fluoro-4-(7-pyridin-2-ylimidazo[1,2-a]pyridin-3-yl)phenyl]acetamide Chemical compound O1C(C(C)(C)C)=CC(NC(=O)CC=2C(=CC(=CC=2)C=2N3C=CC(=CC3=NC=2)C=2N=CC=CC=2)F)=N1 XEKBGOVZNHDHET-UHFFFAOYSA-N 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 125000004356 hydroxy functional group Chemical group O* 0.000 abstract 2
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 1
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Neurology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Vascular Medicine (AREA)
- Emergency Medicine (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Neurosurgery (AREA)
- Rheumatology (AREA)
- Ophthalmology & Optometry (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US65598105P | 2005-02-24 | 2005-02-24 | |
| PCT/US2006/006283 WO2006091671A1 (en) | 2005-02-24 | 2006-02-23 | Imidazo (1, 2-a) pyridine compounds as vegf-r2 inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20100677T1 true HRP20100677T1 (hr) | 2011-01-31 |
Family
ID=36587138
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HR20100677T HRP20100677T1 (hr) | 2005-02-24 | 2010-12-07 | IMIDAZO[1,2-a]PIRIDINSKI SPOJEVI KAO INHIBITORI VEGF-R2 |
Country Status (34)
| Country | Link |
|---|---|
| US (1) | US7666879B2 (lv) |
| EP (1) | EP1904494B1 (lv) |
| JP (1) | JP5055136B2 (lv) |
| KR (1) | KR100904938B1 (lv) |
| CN (1) | CN101128461B (lv) |
| AR (1) | AR056186A1 (lv) |
| AT (1) | ATE490254T1 (lv) |
| AU (1) | AU2006216710B2 (lv) |
| BR (1) | BRPI0609047A2 (lv) |
| CA (1) | CA2599124C (lv) |
| CR (1) | CR9331A (lv) |
| CY (1) | CY1111154T1 (lv) |
| DE (1) | DE602006018615D1 (lv) |
| DK (1) | DK1904494T3 (lv) |
| DO (1) | DOP2006000051A (lv) |
| EA (1) | EA011691B1 (lv) |
| ES (1) | ES2354716T3 (lv) |
| HK (1) | HK1118284A1 (lv) |
| HR (1) | HRP20100677T1 (lv) |
| IL (1) | IL184717A (lv) |
| MA (1) | MA29433B1 (lv) |
| MX (1) | MX2007010326A (lv) |
| NO (1) | NO20074666L (lv) |
| NZ (2) | NZ560402A (lv) |
| PE (1) | PE20061098A1 (lv) |
| PL (1) | PL1904494T3 (lv) |
| PT (1) | PT1904494E (lv) |
| RS (1) | RS51590B (lv) |
| SI (1) | SI1904494T1 (lv) |
| TN (1) | TNSN07323A1 (lv) |
| TW (1) | TW200640924A (lv) |
| UA (1) | UA91535C2 (lv) |
| WO (1) | WO2006091671A1 (lv) |
| ZA (1) | ZA200707136B (lv) |
Families Citing this family (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101679408B (zh) * | 2006-12-22 | 2016-04-27 | Astex治疗学有限公司 | 作为fgfr抑制剂的双环杂环化合物 |
| US8131527B1 (en) | 2006-12-22 | 2012-03-06 | Astex Therapeutics Ltd. | FGFR pharmacophore compounds |
| WO2008078100A2 (en) * | 2006-12-22 | 2008-07-03 | Astex Therapeutics Limited | Tricyclic amine derivatives as protein tyrosine kinase inhibitors |
| AU2008226947B2 (en) | 2007-03-08 | 2014-07-17 | The Board Of Trustees Of The Leland Stanford Junior University | Mitochondrial aldehyde dehydrogenase-2 modulators and methods of use thereof |
| GB0720041D0 (en) | 2007-10-12 | 2007-11-21 | Astex Therapeutics Ltd | New Compounds |
| GB0720038D0 (en) | 2007-10-12 | 2007-11-21 | Astex Therapeutics Ltd | New compounds |
| MX2010004244A (es) | 2007-10-17 | 2010-04-30 | Novartis Ag | Derivados de imidazo [i,2-a]-piridina utiles como inhibidores de cinasa tipo activina (alk). |
| GB0810902D0 (en) * | 2008-06-13 | 2008-07-23 | Astex Therapeutics Ltd | New compounds |
| US8354435B2 (en) | 2008-09-08 | 2013-01-15 | The Board Of Trustees Of The Leland Stanford Junior University | Modulators of aldehyde dehydrogenase activity and methods of use thereof |
| JP2012506856A (ja) | 2008-10-28 | 2012-03-22 | ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティ | アルデヒドデヒドロゲナーゼのモジュレーターおよびその使用方法 |
| JO3265B1 (ar) | 2008-12-09 | 2018-09-16 | Novartis Ag | مثبطات بيريديلوكسى اندولات vegf-r2 واستخدامها لعلاج المرض |
| US8278302B2 (en) | 2009-04-08 | 2012-10-02 | Boehringer Ingelheim International Gmbh | Substituted piperidines as CCR3 antagonists |
| GB0906472D0 (en) | 2009-04-15 | 2009-05-20 | Astex Therapeutics Ltd | New compounds |
| GB0906470D0 (en) | 2009-04-15 | 2009-05-20 | Astex Therapeutics Ltd | New compounds |
| TW201124391A (en) | 2009-10-20 | 2011-07-16 | Lundbeck & Co As H | 2-substituted-ethynylthiazole derivatives and uses of same |
| GB201009731D0 (en) | 2010-06-10 | 2010-07-21 | Pulmagen Therapeutics Inflamma | Kinase inhibitors |
| UA109290C2 (uk) | 2010-10-07 | 2015-08-10 | Спільні кристали і солі інгібіторів ccr3 | |
| WO2012149106A1 (en) | 2011-04-29 | 2012-11-01 | The Board Of Trustees Of The Leland Stanford Junior University | Compositions and methods for increasing proliferation of adult salivary stem cells |
| US8680280B2 (en) * | 2012-04-02 | 2014-03-25 | Boehringer Ingelheim International Gmbh | Process for the manufacturing of CRR inhibitors |
| US10213421B2 (en) | 2012-04-04 | 2019-02-26 | Alkahest, Inc. | Pharmaceutical formulations comprising CCR3 antagonists |
| JP6430383B2 (ja) | 2012-09-28 | 2018-11-28 | ヴァンダービルト ユニバーシティーＶａｎｄｅｒｂｉｌｔ Ｕｎｉｖｅｒｓｉｔｙ | 選択的ｂｍｐ阻害剤としての縮合複素環化合物 |
| JP6007339B2 (ja) * | 2012-11-29 | 2016-10-12 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | イミダゾピリジン誘導体 |
| EP2970124B1 (en) | 2013-03-14 | 2019-05-22 | The Board of Trustees of the Leland Stanford Junior University | Mitochondrial aldehyde dehydrogenase-2 modulators and methods of use thereof |
| BR112016013734A2 (pt) | 2013-12-16 | 2017-08-08 | Asana Biosciences Llc | Composto, composição farmacêutica, kit, e uso de um composto |
| CN103772308B (zh) * | 2013-12-31 | 2015-11-18 | 北京颖泰嘉和生物科技股份有限公司 | 5-氨基-3-(1-乙基-1-甲基丙基)异噁唑中间体的制备方法和异噁草胺的制备方法 |
| JP6612857B2 (ja) * | 2014-06-03 | 2019-11-27 | ジ・アリゾナ・ボード・オブ・リージェンツ・オン・ビハーフ・オブ・ザ・ユニバーシティー・オブ・アリゾナ | ベンゾイミダゾールアナログおよび関連方法 |
| HUE046008T2 (hu) | 2014-07-17 | 2020-02-28 | Sunshine Lake Pharma Co Ltd | I-(5-terc-butil)-izoxazol-3-il)-3-(4-((feniI)-etinil)-fenil)-kabamid származékok, valamint az ezekkel rokon vegyületek FLT-3 inhibitorokként rák kezelésére |
| CN104163790B (zh) * | 2014-08-19 | 2016-02-10 | 贵州威顿晶磷电子材料股份有限公司 | 一种2-氨基-4-甲基-5溴吡啶的制备工艺 |
| WO2017019804A2 (en) | 2015-07-28 | 2017-02-02 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
| AU2016315881B2 (en) * | 2015-09-03 | 2019-09-19 | The Arizona Board Of Regents On Behalf Of The University Of Arizona | Small molecule inhibitors of DYRK1A and uses thereof |
| WO2017161045A1 (en) * | 2016-03-16 | 2017-09-21 | Plexxikon Inc. | Compounds and methods for kinase modulation and indications therefore |
| US10745400B2 (en) | 2018-03-14 | 2020-08-18 | Vanderbuilt University | Inhibition of BMP signaling, compounds, compositions and uses thereof |
| US10239885B1 (en) | 2018-06-18 | 2019-03-26 | Avista Pharma Solutions, Inc. | Compound 1-[2-[4-(2-ethyl-6,8-dimethylimidazo[1,2-α]pyrazin-3-yl)phenyl]ethyl]-3-(p-tolylsulfonyl)urea as a prostaglandin EP4 receptor antagonist |
| CA3125353A1 (en) | 2018-12-31 | 2020-07-09 | Biomea Fusion, Llc | Inhibitors of menin-mll interaction |
| JP2022516057A (ja) | 2018-12-31 | 2022-02-24 | バイオメア フュージョン，エルエルシー | メニン－ｍｌｌ相互作用の不可逆的阻害剤 |
| MX2021009082A (es) | 2019-01-30 | 2021-09-08 | Avista Pharma Solutions Inc | Compuestos quimicos. |
| US11512088B2 (en) | 2019-01-30 | 2022-11-29 | Avista Pharma Solutions, Inc. | Synthetic process and intermediates |
| JP7323218B2 (ja) * | 2019-02-18 | 2023-08-08 | 深▲チェン▼市塔吉瑞生物医薬有限公司 | 置換された縮合芳香環誘導体、その組成物、およびそれらの使用 |
| CN114466847A (zh) * | 2019-06-25 | 2022-05-10 | 西诺普塞疗法公司 | 用于治疗癌症的化合物 |
| CN112778294A (zh) * | 2021-01-07 | 2021-05-11 | 苏州安睿药业有限公司 | 5-氨基异噁唑衍生物及其在制备多激酶抑制剂中的应用 |
| EP4387972A1 (en) | 2021-08-20 | 2024-06-26 | Biomea Fusion, Inc. | Crystalline form of n-[4-[4-(4-morpholinyl)-7h-pyrrolo[2,3-d]pyrimidin-6-yl]phenyl]-4-[[3(r)-[(1-oxo -2-propen-1-yl)amino]-1-piperidinyl]methyl]-2-pyridinecarboxamide, an irreversible menin-mll inhibitor for the treatment of cancer |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0888310B1 (en) | 1996-03-15 | 2005-09-07 | AstraZeneca AB | Cinnoline derivatives and use as medicine |
| AU744939B2 (en) | 1997-09-26 | 2002-03-07 | Merck & Co., Inc. | Novel angiogenesis inhibitors |
| ATE312823T1 (de) | 1999-07-09 | 2005-12-15 | Boehringer Ingelheim Pharma | Verfahren zur herstellung heteroarylsubstituierter ureaverbindungen |
| US6492529B1 (en) | 2000-01-18 | 2002-12-10 | Boehringer Ingelheim Pharmaceuticals, Inc. | Bis pyrazole-1H-pyrazole intermediates and their synthesis |
| ES2284887T3 (es) | 2001-07-11 | 2007-11-16 | Boehringer Ingelheim Pharmaceuticals Inc. | Metodos para tratar enfermedades transmitidas por citocinas. |
| JP2003313126A (ja) * | 2002-04-23 | 2003-11-06 | Sankyo Co Ltd | イミダゾピリジン誘導体を有効成分とする医薬 |
| DE60318198T2 (de) * | 2002-05-02 | 2008-12-04 | Merck & Co., Inc. | Tyrosinkinase-hemmer |
| AU2003298942A1 (en) * | 2002-12-11 | 2004-06-30 | Merck And Co., Inc. | Tyrosine kinase inhibitors |
| US7550470B2 (en) * | 2002-12-11 | 2009-06-23 | Merck & Co. Inc. | Substituted pyrazolo[1,5-A]pyrimidines as tyrosine kinase inhibitors |
| AU2004265189B2 (en) | 2003-08-15 | 2010-03-04 | Banyu Pharmaceutical Co., Ltd. | Imidazopyridine derivatives |
-
2006
- 2006-02-22 DO DO2006000051A patent/DOP2006000051A/es unknown
- 2006-02-23 CA CA2599124A patent/CA2599124C/en not_active Expired - Fee Related
- 2006-02-23 JP JP2007557126A patent/JP5055136B2/ja not_active Expired - Fee Related
- 2006-02-23 US US11/816,416 patent/US7666879B2/en not_active Expired - Fee Related
- 2006-02-23 NZ NZ560402A patent/NZ560402A/en not_active IP Right Cessation
- 2006-02-23 UA UAA200709559A patent/UA91535C2/ru unknown
- 2006-02-23 NZ NZ584753A patent/NZ584753A/en not_active IP Right Cessation
- 2006-02-23 EP EP06735794A patent/EP1904494B1/en active Active
- 2006-02-23 AU AU2006216710A patent/AU2006216710B2/en not_active Ceased
- 2006-02-23 CN CN2006800060044A patent/CN101128461B/zh not_active Expired - Fee Related
- 2006-02-23 RS RS20110042A patent/RS51590B/en unknown
- 2006-02-23 PE PE2006000219A patent/PE20061098A1/es not_active Application Discontinuation
- 2006-02-23 SI SI200630871T patent/SI1904494T1/sl unknown
- 2006-02-23 TW TW095106022A patent/TW200640924A/zh unknown
- 2006-02-23 AT AT06735794T patent/ATE490254T1/de active
- 2006-02-23 PT PT06735794T patent/PT1904494E/pt unknown
- 2006-02-23 ES ES06735794T patent/ES2354716T3/es active Active
- 2006-02-23 DK DK06735794.7T patent/DK1904494T3/da active
- 2006-02-23 MX MX2007010326A patent/MX2007010326A/es active IP Right Grant
- 2006-02-23 PL PL06735794T patent/PL1904494T3/pl unknown
- 2006-02-23 BR BRPI0609047-8A patent/BRPI0609047A2/pt not_active IP Right Cessation
- 2006-02-23 DE DE602006018615T patent/DE602006018615D1/de active Active
- 2006-02-23 EA EA200701802A patent/EA011691B1/ru not_active IP Right Cessation
- 2006-02-23 WO PCT/US2006/006283 patent/WO2006091671A1/en active Application Filing
- 2006-02-23 KR KR1020077019338A patent/KR100904938B1/ko not_active IP Right Cessation
- 2006-02-23 AR ARP060100668A patent/AR056186A1/es not_active Application Discontinuation
-
2007
- 2007-07-19 IL IL184717A patent/IL184717A/en not_active IP Right Cessation
- 2007-08-22 CR CR9331A patent/CR9331A/es not_active Application Discontinuation
- 2007-08-23 ZA ZA200707136A patent/ZA200707136B/xx unknown
- 2007-08-23 TN TNP2007000323A patent/TNSN07323A1/en unknown
- 2007-09-13 NO NO20074666A patent/NO20074666L/no not_active Application Discontinuation
- 2007-09-24 MA MA30233A patent/MA29433B1/fr unknown
-
2008
- 2008-08-25 HK HK08109446.3A patent/HK1118284A1/xx not_active IP Right Cessation
-
2010
- 2010-12-07 HR HR20100677T patent/HRP20100677T1/hr unknown
-
2011
- 2011-02-03 CY CY20111100115T patent/CY1111154T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20100677T1 (hr) | IMIDAZO[1,2-a]PIRIDINSKI SPOJEVI KAO INHIBITORI VEGF-R2 | |
| HRP20180916T1 (hr) | Inhibitori demetilaze od lsd1 na bazi arilciklopropilamina i njihova medicinska uporaba | |
| RU2397168C2 (ru) | Производные тиофена в качестве ингибиторов снк 1 | |
| HRP20210957T1 (hr) | Spojevi inhibitori autotaksina | |
| HRP20180081T1 (hr) | Fuzionirani triciklični heterociklični spojevi kao inhibitori hiv integraze | |
| CA2445333A1 (en) | Quinoline derivatives and quinazoline derivatives having azolyl group | |
| JP2008531574A5 (lv) | ||
| HRP20170352T1 (hr) | Spojevi bis(fluroalkil)-1,4-benzodiazepinona kao notch inhibitori | |
| GEP20125379B (en) | 2 -pyridine carboxamide derivatives as sodium channel modulators | |
| NO20083434L (no) | Benzamid- og heteroarenderivater | |
| HRP20140975T1 (hr) | Derivati n-(3-amino-hinoksalin-2-il)-sulfonamida i njihova uporaba kao inhibitora fosfatidilinozitol 3-kinaze | |
| AR053364A1 (es) | Compuesto de 1h-imidazo 84,5-c) piridin -2- ilo, composicion farmaceutica que lo comprende, proceso para prepararla y su uso para preparar un medicamento para tratamiento de cancer o artritis | |
| BR112014019478A2 (pt) | composto ou um sal farmacologicamente aceitável do mesmo, composição farmacêutica, uso de um composto ou de um sal farmacologicamente aceitável do mesmo, formulação inibidor do canal de sódio, métodos para tratamento e/ou prevenção de dor e de uma doença. | |
| HRP20211728T1 (hr) | Rsv antivirusni pirazolo- i triazolo-pirimidinski spojevi | |
| IL264982B (en) | Hetero(aryl)cyclopropylamine compounds as lsd1 inhibitors | |
| HRP20130202T1 (hr) | Spojevi imidazo[1,2-a] pirazina za lijeäśenje virusnih infekcija kao što je hepatitis | |
| NZ717119A (en) | Aryl-or heteroaryl-substituted benzene compounds | |
| AR041009A1 (es) | Compuestos heterociclicos nitrogenados que presentan actividad inhibitoria contra la integrasa del vih | |
| JP2009541223A5 (lv) | ||
| RU2004121161A (ru) | Замещенные 2-тио-3,5-дициано-4-фенил-6-аминопиридины и их применение | |
| RS107504A (en) | Benzofused heteroaryl amide derivatives of thienopyridines useful as therapeutic agents, pharmaceutical compostions including the same, and methods for their use | |
| AR062886A1 (es) | Compuestos de tiazol pirazolopirimidina, composicion farmaceutica que lo comprende y su uso para preparar un medicamento | |
| WO2009064747A3 (en) | 4(-3-(-2-(phenyl) morpholino)-2-oxopyrrolidin-1-yl)-n-(thiazol-2-yl) benzenesulfon amide derivatives and related compounds as modulators of ion channels for the treatment of pain | |
| AR047466A1 (es) | Compuestos derivados de 3h - imidazo[4,5 - b]piridina con actividad inhibidora de quinasa, composiciones farmacéuticas que los contienen como principio activo y su uso en la fabricacion de un medicamento para el tratatmiento de neoplasmas susceptibles. | |
| CA2744756A1 (en) | Monocarbams and their use as antibacterial agent |